Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers.
Lung cancer is the leading cause of cancer-related mortality worldwide, leading to an estimated 1.4 million deaths in 2010 (ref. 1). The discovery of recurrent mutations in the epidermal growth factor receptor (EGFR) kinase, as well as fusions involving anaplastic lymphoma kinase (ALK), has led to a marked change in the treatment of patients with lung adenocarcinoma, the most common type of lung cancer2,3,4,5. More recent data have suggested that targeting mutations in BRAF, AKT1, ERBB2 and PIK3CA and fusions that involve ROS1 and RET may also be successful6,7. Unfortunately, activating mutations in EGFR and ALK fusions are typically not present in the second most common type of lung cancer, lung squamous cell carcinoma (SQCC)8, and targeted agents developed for lung adenocarcinoma are largely ineffective against lung SQCC.
Although no comprehensive genomic analysis of lung SQCCs has been reported, single-platform studies have identified regions of somatic copy number alterations in lung SQCCs, including amplification of SOX2, PDGFRA and FGFR1 and/or WHSC1L1 and deletion of CDKN2A9,10. DNA sequencing studies of lung SQCCs have reported recurrent mutations in several genes, including TP53, NFE2L2, KEAP1, BAI3, FBXW7, GRM8, MUC16, RUNX1T1, STK11 and ERBB4 (refs 11, 12). DDR2 mutations and FGFR1 amplification have been nominated as therapeutic targets13,14,15.
We have conducted a comprehensive study of lung SQCCs from a large cohort of patients as part of The Cancer Genome Atlas (TCGA) project. The twin aims are to characterize the genomic and epigenomic landscape of lung SQCC and to identify potential opportunities for therapy. We report an integrated analysis based on DNA copy number, somatic exonic mutations, messenger RNA sequencing, mRNA expression and promoter methylation for 178 histopathologically reviewed lung SQCCs, in addition to whole genome sequencing (WGS) of 19 samples and microRNA sequencing of 159 samples (Supplementary Table 1.1). Demographic and clinical data and results of the genomic analyses can be downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/docs/publications/lusc_2012/).
Samples and clinical data
Tumour samples were obtained from 178 patients with previously untreated stage I–IV lung SQCC. Germline DNA was obtained from adjacent, histologically normal tissues resected at the time of surgery (n = 137) or from peripheral blood (n = 41). All patients provided written informed consent to conduct genomic studies in accordance with local Institutional Review Boards. The demographic characteristics are described in Supplementary Table 1.2. The median follow-up for the cohort was 15.8 months, and 60% of patients were alive at the time of the last follow-up (data updated in November 2011). Ninety-six per cent of the patients had a history of tobacco use, similar to previous reports for North American patients with lung SQCC16. DNA and RNA were extracted from patient specimens and measured by several genomic assays, which included standard quality-control assessments (Supplementary Methods, sections 2–8). A committee of experts in lung cancer pathology performed a further review of all samples to confirm the histological subtype (Supplementary Fig. 1.1 and Supplementary Methods, section 1).
Somatic DNA alterations
The lung SQCCs analysed in this study display a large number and variety of DNA alterations, with a mean of 360 exonic mutations, 323 altered copy number segments and 165 genomic rearrangements per tumour.
Copy number alterations were analysed using several platforms. Analysis of single nucleotide polymorphism (SNP) 6.0 array data across the set of 178 lung SQCCs identified a high rate of copy number alteration (mean of 323 segments) when compared with other TCGA projects (as of 1 February 2012), including ovarian cancer (477 segments)17, glioblastoma multiforme (282 segments)18, colorectal carcinoma (213 segments), breast carcinoma (282 segments) and renal cell carcinoma (156 segments) (P < 1 × 10−15 by Fisher’s exact test). These segments gave rise to regions of both focal and broad somatic copy number alterations (SCNAs), with a mean of 47 focal and 23 broad events per tumour (broad events defined as ≥50% of the length of the chromosome arm). There was strong concordance between the three independent copy number assays for all regions of SCNA (Supplementary Figs 2.1–2.4).
At the level of whole chromosome arm SCNAs, lung SQCCs exhibit many similarities to 205 cases of lung adenocarcinoma analysed by TCGA (Supplementary Fig. 2.1a). The most notable difference between these cancers is selective amplification of chromosome 3q in lung SQCC, as has been reported9,19. Using the SNP 6.0 array platform and GISTIC 2.0 (refs 20, 21), we identified regions of significant copy number alteration (Supplementary Methods, section 2). There were 50 peaks of significant amplification or deletion (Q < 0.05), several of which included SCNAs previously seen in lung SQCCs including SOX2, PDGFRA and/or KIT, EGFR, FGFR1 and/or WHSC1L1, CCND1 and CDKN2A9,10,19 (Supplementary Fig. 2.1b and Supplementary Data 2.1 and 2.2). Other peaks defined regions of SCNA reported for the first time, including amplifications of chromosomal segments containing NFE2L2, MYC, CDK6, MDM2, BCL2L1 and EYS and deletions of FOXP1, PTEN and NF1 (Supplementary Fig. 2.1b).
Whole exome sequencing of 178 lung SQCCs and matched germline DNA targeted 193,094 exons from 18,863 genes. The mean sequencing coverage across targeted bases was 121×, with 83% of target bases above 30× coverage. We identified a total of 48,690 non-silent mutations with a mean of 228 non-silent and 360 total exonic mutations per tumour, corresponding to a mean somatic mutation rate of 8.1 mutations per megabase (Mb) and median of 8.4 per Mb. That rate is higher than rates observed in other TCGA projects including acute myelogenous leukaemia (0.56 per Mb), breast carcinoma (1.0 per Mb), ovarian cancer17 (2.1 per Mb), glioblastoma multiforme18 (2.3 per Mb) and colorectal carcinoma (3.2 per Mb) (data as of 1 February 2012, P < 2.2 × 10−16 by t-test or Wilcoxon’s rank sum test for lung SQCC versus all others). In lung SQCC, CpG transitions and transversions were the most commonly observed mutation types, with mean rates of 9.9 and 10.7 per sequenced megabase of CpG context, respectively, for a total mutation rate of 20.6 per Mb. At non-CpG sites, transversions at C:G sites were more common than transitions (7.3 versus 2.9 per Mb; total = 10.2 per Mb) and more common than transversions or transitions at A:T sites (1.5 versus 1.3 per Mb; total = 2.8 per Mb).
Significantly mutated genes were identified using a modified version of the MutSig algorithm (Supplementary Methods, section 3)22,23. We identified 10 genes with a false discovery rate (FDR) Q value < 0.1 (Supplementary Table 3.1): TP53, CDKN2A, PTEN, PIK3CA, KEAP1, MLL2, HLA-A, NFE2L2, NOTCH1 and RB1, all of which demonstrated robust evidence of gene expression as defined by reads per kilobase of exon model per million mapped reads (RPKM) > 1 (Fig. 1). TP53 mutation was observed in 81% of samples by automated analysis; visual review of sequencing reads identified a further 9% of samples with potential mutations in regions of sub-optimal coverage or in samples with low purity. Most observed mutations in NOTCH1 (8 out of 17) were truncating alterations, suggesting loss-of-function, as has recently been reported for head and neck SQCCs22,24. Mutations in HLA-A were also almost exclusively nonsense or splice site events (7 out of 8).
To increase our statistical power to detect mutated genes in the setting of the observed high background mutation rate, we performed a secondary MutSig analysis only considering genes previously observed to be mutated in cancer according to the COSMIC database. This yielded 12 other genes with FDR < 0.1: FAM123B (also known as WTX), HRAS, FBXW7, SMARCA4, NF1, SMAD4, EGFR, APC, TSC1, BRAF, TNFAIP3 and CREBBP (Supplementary Table 3.1). Both the spectrum and the frequency of EGFR mutations differed from those seen in lung adenocarcinomas. The two most common alterations in lung adenocarcinoma, Leu858Arg and inframe deletions in exon 19, were absent, whereas two Leu861Gln mutations were detected in EGFR.
As described in Supplementary Fig. 3.1, we verified somatic mutations by performing an independent hybrid-recapture of 76 genes in all samples. A total of 1,289 mutations were assayed, and we achieved satisfactory coverage to have power to verify at 1,283 positions. We validated 1,235 mutations (96.2%) (Supplementary Fig. 3.1 and Supplementary Methods, section 3). We also verified mutation calls using WGS and RNA sequencing data with similar results (Supplementary Figs 3.1, 4.3 and Supplementary Methods, sections 3 and 4).
WGS was performed for 19 tumour/normal pairs with a mean computed coverage of 54×. A mean of 165 somatic rearrangements was found per lung SQCC tumour pair (Supplementary Fig. 3.2), a value in excess of that reported for WGS studies of other tumour types including colorectal carcinoma (75)25, prostate carcinoma (108)26, multiple myeloma (21)23 and breast cancer (90)27. Although most inframe coding fusions detected in WGS were validated by RNA sequencing, no recurrent rearrangements predicted to generate fusion proteins were identified (Supplementary Data 3.1 and 4.1).
Somatically altered pathways
Many of the somatic alterations we have identified in lung SQCCs seem to be drivers of pathways important to the initiation or progression of the cancer. Specifically, genes involved in the oxidative stress response and squamous differentiation were frequently altered by mutation or SCNA. We observed mutations and copy number alterations of NFE2L2 and KEAP1 and/or deletion or mutation of CUL3 in 34% of cases (Fig. 2). NFE2L2 and KEAP1 code for proteins that bind to each other, have been shown to regulate the cell response to oxidative damage, chemo- and radiotherapy, and are somatically altered in a variety of cancer types28,29. We found mutations in NFE2L2 almost exclusively in one of two KEAP1 interaction motifs, DLG or ETGE. Mutations in KEAP1 and CUL3 showed a pattern consistent with loss-of-function and were mutually exclusive with mutations in NFE2L2 (Figs 1c and 2). PARADIGM SHIFT30 analysis predicts that mutations in NFE2L2 and KEAP1 exert a considerable functional effect (Supplementary Fig. 7.C.1, 7.C.2 and Supplementary Methods, section 7).
We also found alterations in genes with known roles in squamous cell differentiation in 44% of samples, including overexpression and amplification of SOX2 and TP63, loss-of-function mutations in NOTCH1, NOTCH2 and ASCL4 and focal deletions in FOXP1 (Fig. 2). Although NOTCH1 has been well characterized as an oncogene in haematological cancers31, NOTCH1 and NOTCH2 truncating mutations have been reported in cutaneous SQCCs and lung SQCCs32. Truncating mutations in ASCL4 are the first to be reported in human cancer and may have a lineage role given the requirement for ASCL1 for survival of small-cell lung cancer cells33. Alterations in NOTCH1, NOTCH2 and ASCL4 were mutually exclusive and exhibited minimal overlap with amplification of TP63 and/or SOX2 (Fig. 2), suggesting that aberrations in those modulators of squamous cell differentiation have overlapping functional consequences.
mRNA expression profiling and subtype classification
Whole-transcriptome expression profiles were generated by RNA sequencing for the entire cohort and by microarrays for a 121-sample subset. Of 20,502 genes analysed, the mean RNA coverage indices were 19× and 6,420 RPKM (Supplementary Fig. 4.1 and Supplementary Methods, section 4). Previously reported lung SQCC gene expression-subtype signatures34 were applied to both of the expression platforms, yielding four subtypes designated as classical (36%), basal (25%), secretory (24%) and primitive (15%). The concordance of subtypes between the two platforms was high (94% agreement) (Supplementary Fig. 4.2). Considerable correlations were found between the expression subtypes and genomic alterations in copy number, mutation and methylation (Fig. 3). The classical subtype was characterized by alterations in KEAP1, NFE2L2 and PTEN, as well as pronounced hypermethylation and chromosomal instability. The 3q26 amplicon was present in all of the subtypes, but it was most characteristic of the classical subtype, which also showed the greatest overexpression of three known oncogenes on 3q: SOX2, TP63 and PIK3CA. RNA sequencing data suggested that high expression levels of TP63, in samples with and without amplification of TP63, were associated with dominant expression of the deltaN isoform (also called p40), which lacks the amino-terminal transactivation domain, compared with the longer isoform, called tap63 (89% of tumours overexpressed deltaN compared with tap63; P < 2.2 × 10−16). The short deltaN isoform is thought to function as an oncogene35,36, and its expression was most enriched in the classical subtype. By contrast, the primitive expression subtype more commonly exhibited RB1 and PTEN alterations, and the basal expression subtype showed NF1 alterations (Fig. 3). Amplification of FGFR1 and WHSC1L1 was anticorrelated with the classical subtype and specifically with NFE2L2 or KEAP1 mutated samples. Although CDKN2A alterations are common in lung SQCCs, they are not associated with any particular expression subtype (Fig. 3).
Independent clustering of miRNA and methylation data indicated association with expression subtypes. The highest overall methylation was seen in the classical subtype (Fig. 3, Supplementary Figs 5.1 and 6.1, Supplementary Methods, sections 5 and 6, Supplementary Data 6.1 and 6.2 and Supplementary Table 5.1). Integrative clustering (iCluster)37 of mRNA, miRNA, methylation, SCNA and mutation data demonstrated concordance with the mRNA expression subtypes and associated alterations (Fig. 3, Supplementary Fig. 7.A.1 and Supplementary Methods, section 7). Independent correlation of somatic mutations, copy number alterations and gene expression signatures revealed notable subtype associations with alterations in the TP53, PI3K, RB1 and NFE2L2/KEAP1 pathways (Supplementary Fig. 7.B.1 and Supplementary Methods, section 7).
Analysis of the CDKN2A locus
Integrated multiplatform analyses showed that CDKN2A, a known tumour suppressor gene in lung SQCC38 that encodes the p16INK4A and p14ARF proteins, is inactivated in 72% of cases of lung SQCC (Fig. 4a and Supplementary Data 7.1)—by epigenetic silencing by methylation (21%), inactivating mutation (18%), exon 1β skipping (4%) and homozygous deletion (29%).
Analysis of mRNA expression across the CDKN2A locus revealed four distinct patterns of expression: complete absence of both p16INK4 and ARF (33%); expression of high levels of both p16INK4 and ARF (31%); high expression of ARF and absence of p16INK4 (31%); or expression of a transcript that represents a splicing of exon 1β from ARF with the shared exon 3 of ARF and p16INK4, generating a premature stop codon (4%) (Supplementary Fig. 4.4). Almost all of the cases completely lacking p16INK4 and ARF expression showed homozygous deletion (Fig. 4b and Supplementary Data 7.1). In one case, p16INK4 expression was detected but analysis of WGS data demonstrated an intergenic fusion event that resulted in detectable transcription between exon 1α p16INK4 and exon 18 of KIAA1797 (Fig. 4b, c). Interestingly, combined analysis of WGS and RNA sequencing data identified tumour suppressor gene inactivation by intra- or interchromosomal rearrangement in PTEN, NOTCH1, ARID1A, CTNNA2, VHL and NF1, in eight further cases (Supplementary Data 3.1 and 4.1).
In addition to homozygous deletion, there are frequent mutational events in CDKN2A (Fig. 4b and Supplementary Data 7.1). These account for 45% of the 56 cases with high p16INK4 and ARF expression. Furthermore, methylation of the exon 1α promoter accounts for many other cases of CDKN2A inactivation (70% of lung SQCCs with ARF expression in the absence of detectable p16INK4). Seven other tumours in the high-ARF/low-INK4A group had documented mutations of INK4A, primarily nonsense mutations, suggesting nonsense-mediated decay as a mechanism. Of the 28% of tumours without CDKN2A alterations, RB1 mutations were identified in eight cases and CDK6 amplification in one case (Fig. 4d).
Molecularly targeted agents are now commonly used in patients with adenocarcinoma of the lung, whereas no effective targeted agents have been developed specifically for lung SQCCs13. We analysed our genomic data for evidence of the two common genomic alterations in adenocarcinomas of the lung: EGFR and KRAS mutations. Only one sample had a KRAS codon 61 mutation, and there were no exon 19 deletions or Leu858Arg mutations in EGFR. However, amplifications of EGFR were found in 7% of cases, as were two instances of the Leu861Gln EGFR mutation, which confers sensitivity to erlotinib and gefitinib39.
The presence of new potential therapeutic targets in lung SQCC was suggested by the observation that 96% (171 out of 178) of tumours contain one or more mutations in tyrosine kinases, serine/threonine kinases, phosphatidylinositol-3-OH kinase (PI(3)K) catalytic and regulatory subunits, nuclear hormone receptors, G-protein-coupled receptors, proteases and tyrosine phosphatases (Supplementary Fig. 7.D.1a and Supplementary Data 7.2 and 7.3). From 50 to 77% of the mutations were predicted to have a medium or high functional effect as determined by the mutation assessor score40 (Supplementary Fig. 7.D.1a), and 39% of tyrosine and 42% of serine/threonine kinase mutations were located in the kinase domain. Many of the alterations were in known oncogenes and tumour suppressors, as defined in the COSMIC database (Supplementary Data 7.3).
We selected potential therapeutic targets based on several features, including (1) availability of a US Food and Drug Administration (FDA)-approved targeted therapeutic agent or one under study in current clinical trials (Supplementary Data 7.2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score40. Using those criteria, we identified 114 cases with somatic alteration of a potentially targetable gene (64%) (Supplementary Fig. 7.D.1b and Supplementary Data 7.4). Among these, we identified three families of tyrosine kinases, the erythroblastic leukaemia viral oncogene homologues (ERBBs), fibroblast growth factor receptors (FGFRs) and Janus kinases (JAKs), all of which were found to be mutated and/or amplified41. As discussed for EGFR, the mutational spectra in these potential therapeutic targets differed from those in lung adenocarcinoma (Supplementary Fig. 7.D.2)42.
To complement a gene-centred search for potential therapeutic targets, we analysed core cellular pathways known to represent potential therapeutic vulnerabilities: PI(3)K/AKT, receptor tyrosine kinase (RTK) and RAS. Analysis of the 178 lung SQCCs revealed alteration in at least one of those pathways in 69% of samples after restriction of the analysis to mutations confirmed by RNA sequencing and to amplifications associated with overexpression of the target gene (Fig. 5). Mutational events that have been curated in COSMIC are also shown in Supplementary Fig. 7D.2, as is the distribution of mutations, amplifications and overexpression of the genes depicted in Fig. 5. (A summary of all samples and their significant mutations and copy number alterations, including alterations in Fig. 5, is shown in Supplementary Data 7.5.) Specifically, one of the components of the PI(3)K/AKT pathway was altered in 47% of tumours and RTK signalling probably affected by events such as EGFR amplification, BRAF mutation or FGFR amplification or mutation in 26% of tumours (Fig. 5 and Supplementary Fig. 7.D.3). Alterations in the PI(3)K/AKT pathway genes were mutually exclusive with EGFR alterations as identified by MEMo43 (Supplementary Fig. 7.D.4.). Although the dependence of lung SQCC on many of these individual alterations remains to be defined functionally, this analysis suggests new areas for potential therapeutic development in this cancer.
Lung SQCCs are characterized by a high overall mutation rate of 8.1 mutations per megabase and marked genomic complexity. Similar to high-grade serous ovarian carcinoma17, almost all lung SQCCs display somatic mutation of TP53. There were also frequent alterations in the following pathways: CDKN2A/RB1, NFE2L2/KEAP1/CUL3, PI3K/AKT and SOX2/TP63/NOTCH1 pathways, providing evidence of common dysfunction in cell cycle control, response to oxidative stress, apoptotic signalling and/or squamous cell differentiation. Pathway alterations clustered according to expression-subtype in many cases, suggesting that those subtypes have a biological basis.
A role for somatic mutation in the cancer hallmark of avoiding immune destruction44 is suggested by the presence of inactivating mutations in the HLA-A gene. Somatic loss-of-function alterations of HLA-A have not been reported previously in genomic studies of lung cancer. Given the recently reported efficacy of anti-programmed death 1 (PD1)45 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibodies in non-small-cell lung cancer46, these HLA-A mutations suggest a possible role for genotypic selection of patients for immunotherapies.
Targeted kinase inhibitors have been successfully used for the treatment of lung adenocarcinoma but minimally so in lung SQCC. The observations reported here suggest that a detailed understanding of the possible targets in lung SQCCs may identify targeted therapeutic approaches. Whereas EGFR and KRAS mutations, the two most common oncogenic aberrations in lung adenocarcinoma, are extremely rare in lung SQCC, alterations in the FGFR kinase family are common. Lung SQCCs also share many alterations in common with head and neck squamous cell carcinomas without evidence of human papilloma virus infection, including mutation in PIK3CA, PTEN, TP53, CDKN2A, NOTCH1 and HRAS22,24, suggesting that the biology of these two diseases may be similar.
The current study has identified a potentially targetable gene or pathway alteration in most lung SQCC samples studied. The data presented here can help to organize efforts to analyse lung SQCC clinical tumour specimens for a panel of specific, actionable mutations to select patients for appropriately targeted clinical trials. These data could thereby help to facilitate effective personalized therapy for this deadly disease.
All specimens were obtained from patients with appropriate consent from the relevant Institutional Review Board. DNA and RNA were collected from samples using the Allprep kit (Qiagen). We used commercial technology for capture and sequencing of exomes from tumour DNA and normal DNA and whole-genome shotgun sequencing. Significantly mutated genes were identified by comparing them with expectation models based on the exact measured rates of specific sequence lesions. GISTIC23,24 analysis of the circular-binary-segmented Affymetrix SNP 6.0 copy number data was used to identify recurrent amplification and deletion peaks. Consensus clustering approaches were used to analyse mRNA, miRNA and methylation subtypes using previous approaches20,21,34,38,41,44.
World Health Organization Cancer, fact sheet no. 297 〈http://www.who.int/mediacentre/factsheets/fs297/en/〉 (accessed, February 2012)
Soda, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007)
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004)
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004)
Pao, W. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004)
Felip, E., Gridelli, C., Baas, P., Rosell, R. & Stahel, R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. Ann. Oncol. 22, 1507–1519 (2011)
Ju, Y. S. et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22, 436–445 (2012)
Rekhtman, N. et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin. Cancer. Res. 18, 1167–1176 (2012)
Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genet. 41, 1238–1242 (2009)
Ramos, A. H. et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol. Ther. 8, 2042–2050 (2009)
Shibata, T. et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl Acad. Sci. USA 105, 13568–13573 (2008)
Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869–873 (2010)
Hammerman, P. S., Sos, M. L., Ramos, A. & Xu, C. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery 1, 78 (2011)
Weiss, J. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010)
Dutt, A. et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6, e20351 (2011)
Kenfield, S. A., Wei, E. K., Stampfer, M. J., Rosner, B. A. & Colditz, G. A. Comparison of aspects of smoking among the four histological types of lung cancer. Tob. Control 17, 198–204 (2008)
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011)
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008)
Tonon, G. et al. High-resolution genomic profiles of human lung cancer. Proc. Natl Acad. Sci. USA 102, 9625–9630 (2005)
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010)
Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011)
Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011)
Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011)
Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1 . Science 333, 1154–1157 (2011)
Bass, A. J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genet. 43, 964–968 (2011)
Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011)
Stephens, P. J. et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462, 1005–1010 (2009)
Singh, A. et al. Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med. 3, e420 (2006)
Singh, A., Bodas, M., Wakabayashi, N., Bunz, F. & Biswal, S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid. Redox Signal. 13, 1627–1637 (2010)
Vaske, C. J. et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237–i245 (2010)
Aster, J. C., Blacklow, S. C. & Pear, W. S. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J. Pathol. 223, 263–274 (2011)
Wang, N. J. et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl Acad. Sci. USA 108, 17761–17766 (2011)
Osada, H., Tatematsu, Y., Yatabe, Y., Horio, Y. & Takahashi, T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res. 65, 10680–10685 (2005)
Wilkerson, M. D. et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin. Cancer Res. 16, 4864–4875 (2010)
Bishop, J. A. et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod. Pathol. 25, 405–415 (2011)
Massion, P. P. et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 63, 7113–7121 (2003)
Shen, R., Olshen, A. B. & Ladanyi, M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics 25, 2906–2912 (2009)
Wikman, H. & Kettunen, E. Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev. Anticancer Ther. 6, 515–530 (2006)
Kancha, R. K., Peschel, C. & Duyster, J. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors. J. Thorac. Oncol. 6, 387–392 (2011)
Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118 (2011)
Govindan, R. Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer. J. Thorac. Oncol. 5, S433 (2010)
Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008)
Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22, 398–406 (2012)
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)
Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010)
Lynch, T. J. et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28, 7531 (2010)
This study was supported by NIH grants U24 CA126561, U24 CA126551, U24 CA126554, U24 CA126543, U24 CA126546, U24 CA126563, U24 CA126544, U24 CA143845, U24 CA143858, U24 CA144025, U24 CA143882, U24 CA143866, U24 CA143867, U24 CA143848, U24 CA143840, U24 CA143835, U24 CA143799, U24 CA143883, U24 CA143843, U54 HG003067, U54 HG003079 and U54 HG003273.
The author declare no competing financial interests.
The primary and processed data used to generate the analyses presented here can be downloaded by registered users fromThe Cancer Genome Atlas (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp, https://cghub.ucsc.edu/ and https://tcga-data.nci.nih.gov/docs/publications/lusc_2012/).
(Participants are arranged by area of contribution and then by institution.)
This file contains Supplementary Methods 1-8, which includes Supplementary Figures and Tables and additional references (see Supplementary Information file pages 1-2 for details). (PDF 16829 kb)
This zipped file contains Supplementary Data files 2.1, 2.2, 3.1, 3.2, 4.1, 4.2 , 6.1, 6.2, 7.1, 7.2, 7.3 (Supplementary table to support figure 5A_Bose_02 23 2012), 7.4 and 7.5 (see Supplementary Information file for details). (ZIP 9075 kb)
Rights and permissions
This article is distributed under the terms of the Creative Commons Attribution-Non-Commercial-Share Alike licence (http://creativecommons.org/licenses/by-nc-sa/3.0/).
About this article
Cite this article
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012). https://doi.org/10.1038/nature11404
This article is cited by
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy
Nature Cancer (2023)
Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning
npj Precision Oncology (2023)
Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
Genome Medicine (2022)
Anti-cancer peptide-based therapeutic strategies in solid tumors
Cellular & Molecular Biology Letters (2022)
Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing
Journal of Translational Medicine (2022)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.